LIN SUE-JEAN 4
4 · Arcutis Biotherapeutics, Inc. · Filed Nov 25, 2025
Insider Transaction Report
Form 4
LIN SUE-JEAN
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-24$8.63/sh+18,052$155,789→ 44,787 total - Sale
Common Stock
2025-11-24$30.78/sh−25,272$777,956→ 26,735 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-24−7,220→ 5,000 totalExercise: $7.51Exp: 2033-05-31→ Common Stock (7,220 underlying) - Exercise/Conversion
Common Stock
2025-11-24$7.51/sh+7,220$54,222→ 52,007 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-24−18,052→ 9,000 totalExercise: $8.63Exp: 2034-06-14→ Common Stock (18,052 underlying)
Footnotes (3)
- [F1]The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
- [F2]The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- [F3]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.